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For the past century, researchers have underscored the “disadvantage” observed in 
respiratory morbidity and mortality of male newborns. In this contemporary review, we 
examine gender differences in preterm infant respiratory morbidity and mortality spe-
cifically appraising differences in the very low birth weight (VLBW) population as well 
as the late preterm (LPT) population. In the era of postnatal surfactant and antenatal 
corticosteroids, the gender gap in neonatal outcomes has not narrowed. Structural, 
physiologic, and hormonal sex differences may be at the root of this disparity. Further 
exploration into the origin of gender differences in respiratory morbidity and neonatal 
mortality will shape future therapies. These therapies may need to be gender specific to 
close the gender gap.
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iNTRODUCTiON
Disparities in neonatal outcomes by demographics such as race, birthweight, and gender have 
been well documented since the early twentieth century (1, 2). In addition to the non-modifiable 
demographics mentioned, gestational age remains the key factor tightly correlated with neonatal 
and infant morbidity and mortality. In 2014, 9.6% of all births occurred before 37 weeks, during the 
preterm period, in the United States (3). Infants born prematurely are more likely to suffer major 
morbidity such as respiratory distress, necrotizing enterocolitis, interventricular hemorrhage (IVH), 
and experience higher mortality than infants born at term (4). Among these morbidities, the greatest 
contributor to infant mortality is respiratory disease. The incidence of respiratory distress syndrome 
(RDS) and subsequent bronchopulmonary dysplasia (BPD) or chronic lung disease (CLD) is higher 
in infants born prematurely due to insufficient surfactant production by type II pneumocytes.
Twenty-five years ago, synthetic surfactant became widely available for postnatal administra-
tion following the landmark study by Fujiwara showing improved survival in artificial surfactant-
exposed neonates and subsequent studies supporting its efficacy (5–7). This was followed shortly 
by a National Institute of Health (NIH) consensus statement published in 1994 supporting the use 
of antenatal corticosteroids to reduce the risk of RDS in preterm infants between 24 and 34 weeks 
at risk for preterm delivery (8). In this consensus statement, use of antenatal corticosteroids was 
associated with reduced rates of RDS, IVH, and overall increase in survival in exposed neonates. 
In recent years, attention has been shifted to the adverse outcomes associated with delivery in the 
late preterm (LPT) period, delivery between 34 and 36 completed weeks, and the disproportion-
ate morbidity and mortality they face compared to term infants (9, 10). Underscoring this was 
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a recent randomized controlled trial illustrating the benefits 
of antenatal corticosteroids for respiratory outcomes in this 
population (11).
Very low birth weight (VLBW) infants, birth weight less 
than 1,500 g, account for only 1% of the preterm population 
but represent greater than 80% of the morbidity and mortality 
attributed to infants born preterm (3). On the other end of 
the spectrum, LPT infants are the fastest growing subgroup of 
neonates and account for 70% of all preterm births (3). In this 
contemporary review, we will examine gender differences in 
preterm infant respiratory morbidity and mortality with hopes 
to shed light on whether the gender disparity gap has narrowed 
over the past two and a half decades. Within the preterm 
population, we will specifically examine differences in respira-
tory morbidity between genders in the VLBW population and 
the LPT population. This will be followed by an assessment 
of gender differences in mortality for preterm neonates with 
emphasis on the VLBW and LPT populations. Finally, we will 
seek to explore physiologic and hormonal reasons why this 
gender disparity exists. Understanding the origin of gender dif-
ferences in respiratory morbidity and overall mortality among 
male and female preterm infants may lead to more targeted 
therapies and streamlined interventions to lessen this inequal-
ity in the future.
To complete this review, the authors used the Scopus database 
and searched using the terms gender, sex, differences, preterm, 
very low birth weight, late preterm, respiratory morbidity, and 
mortality. Abstracts and results were reviewed by two authors 
independently. Manuscripts were excluded if results were not 
stratified by sex or gender, if the population studied did not 
include preterm infants and if the text was not in English. There 
were no geographic restrictions for publication. Gender refers 
to the socially constructed characteristics of men and women, 
while sex refers to the genetic makeup and reproductive organs 
of an individual. For the purposes of this review, the terms sex 
and gender are used interchangeably and are based on clinical 
exam.
GeNDeR DiFFeReNCeS iN PReTeRM 
ReSPiRATORY MORBiDiTY
Since the sentinel study by Wyllie in 1933, many researchers have 
underscored the “disadvantage” observed in the overall morbidity 
and mortality of male newborns (1). Nowhere is this difference 
more evident than in the respiratory morbidity of preterm male 
infants. An ongoing theme throughout the literature is that males 
tend to develop RDS and CLD at a much higher rate than their 
female counterparts. A meta-analysis by Liptzin et al. including 
data from over 500,000 preterm newborn infants highlighted a 
sex ratio of 1.56–1.84 (p < 0.05) in favor of males for respiratory 
distress as well as a sex ratio ranging from 1.22 to 1.38 (p < 0.05) 
again favoring males for CLD compared to females (12–15). 
Males in this study also had increased rates of lower respiratory 
tract infection such as bronchiolitis and pneumonia (sex ratio 
male:female 1.43 and 1.49, respectively), despite similar infection 
rates between sexes.
vLBw Less Than 1,500 g and Gender 
Differences in Respiratory Morbidity
Over the past decade, several studies have reported on the respira-
tory morbidity in the most at-risk preterm group, VLBW neonates. 
In a study of 236 infants less than 29 weeks gestation 36.2% of 
males compared to 19.2% of females developed CLD (p = 0.004) 
(16). Short-term respiratory morbidity was also worse in males 
as they required mechanical ventilation at higher rates within the 
first 6  h of life (60.8 versus 46.2%, p =  0.026) and were found 
to have lower mean arterial pressures (10.5 versus 11.6 mmHg, 
p = 0.042) within the first day of life (16). In a subgroup analysis 
of 175 extremely low birth weight infants, birth weight less than 
1,000  g, males were intubated longer than females (6 versus 
4 days, p = 0.101) and were dosed more frequently (2 doses versus 
1 dose, p = 0.055), particularly in the first 6 h of life (66.3 versus 
47.2%, p =  0.011). However, some of these differences did not 
reach statistical significance. Stevenson et  al. underscored this 
significant difference between the sexes in regards to pulmonary 
morbidity in his report of over 6,700 VLBW infants where males 
had higher rates of RDS (OR 1.41, CI 1.28–1.56), supplemental 
oxygen usage (OR 1.32, CI 1.14–1.54), required higher rates of 
ventilator support (OR 1.34, CI 1.20–1.50), surfactant use (OR 
1.33, CI 1.10–1.60), and developed pneumothorax at a higher 
rate (OR 1.33, CI 1.09–1.62) (17). While significant differences 
were observed in this study, it is also important to note that males 
received antenatal corticosteroids at a lower rate than females (20 
versus 24%, OR 0.80, CI 0.71–0.90) and that overall antenatal 
corticosteroid administration was low, which may be a function 
of the study period (1991–1993) occurring before the 1994 NIH 
consensus statement on antenatal corticosteroids in preterm 
deliveries.
The findings of Brothwood et  al. were very similar to the 
findings of Stevenson et al. In this study the rates of RDS, sup-
plemental oxygen usage and need for mechanical ventilation were 
higher for males than females. This study, unlike many studies 
investigating this population, followed this VLBW cohort for 
2  years and found that early neonatal respiratory morbidity in 
males was associated with higher rates of neurodevelopmental 
abnormalities (67% in males versus 33% in females, p = 0.028) 
including cerebral palsy, sensorineural hearing loss, retinopathy, 
and retardation (18). Also at 2  years of life, males were found 
to have lower hearing and speech scores (94.9 in males versus 
107.3 in females, p < 0.001) and worse personal social skills scores 
(103.6 versus 116.9, p < 0.05) compared to females (18). While 
prematurity may be a major contributing factor to long-term 
neurodevelopmental outcomes, it is also important to under-
stand that other factors may also play a vital role in cognitive and 
emotional responses in early childhood. The impact of the child’s 
environment and postnatal exposures play a large role and were 
not directly addressed in the prior study. Caution must be taken 
when attributing association in this context.
LPT and Gender Differences in  
Respiratory Morbidity
Although earlier gestational ages have been linked to worsened 
respiratory outcomes for decades, there are recent data that 
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suggest male sex, regardless of gestational age, increases the risk 
of adverse respiratory outcomes in newborns. Anadkat et  al. 
reviewed the impact of male sex on the frequency of RDS in 
infants born between 34 and 42  weeks and demonstrated that 
males were at significantly increased risk of respiratory morbidity 
in the LPT period (34 weeks OR 114.1, 35 weeks OR 41.0, and 
36 weeks OR 15.4: overall OR 1.68; p < 0.001 for all values) (14). 
The authors attributed this disparity to hormonal regulation dif-
ferences between the sexes while developing in utero. Although 
hormonal regulation may be one influencer causing this drastic 
difference in respiratory morbidity, the interplay of other factors 
is crucial to understand the divergent physiology of lung develop-
ment between sexes.
These findings are supported by the work of Altman et al. who 
investigated risk factors for moderately preterm (30–34 weeks), 
LPT (35–36 weeks), and term infants (37–41 weeks, reference). 
LPT infants were at increased risk for transient tachypnea of the 
newborn (TTN) (OR 9.5, CI 8.6–10.5) and RDS (OR 38.7, CI 
31.6–47.3) compared to term infants (19). Male gender was found 
to be a risk factor for poor respiratory outcome in this cohort 
(TTN OR 1.25, CI 1.03–1.52 and RDS OR 1.58, CI 1.28–1.96).
GeNDeR DiFFeReNCeS iN  
PReTeRM MORTALiTY
Preterm neonates account for the majority of neonatal morbidity 
and mortality. The major morbidity contributing to mortality in 
this cohort is respiratory insult. The gender differences among 
preterm infants in respiratory morbidity were highlighted 
above. As previously mentioned, the use of postnatal synthetic 
surfactant gained widespread support in the early 1990s. During 
the timeframe where general use of postnatal surfactant was 
being established de Kleine compared neonatal mortality, death 
within the first 28 days of life, between infants born in 1983 and 
those born in 1993. Neonatal mortality decreased from 52.1 
to 31.8% in VLBW infants and from 15.2 to 11.3% in infants 
delivered between 28 and 31  weeks. The effect of male gender 
on mortality increased significantly during the study period with 
gender having no statistically significant effect in 1983 (OR 1.35, 
CI 0.92–1.99) to male sex contributing significantly in 1993 (OR 
2.52, CI 1.42–4.55) (20). Postnatal surfactant alone improved 
overall mortality, but the gender gap in survival remained. Use 
of antenatal corticosteroids gained momentum in the mid-1990s 
shortly after this study. We will examine the impact of both 
antenatal corticosteroids and postnatal surfactant use in our two 
target populations.
vLBw Less Than 1,500 g and Gender 
Differences in Mortality
A study by Jones et al. of over 19,000 Canadian preterm  neonates 
at 17 different centers from 1996 to 1997 showed survival to 
discharge was higher in VLBW females (88.9 versus 85.6%, 
p < 0.05) (21). One criticism of this data was the difference in 
antenatal corticosteroid administration across genders, 69.4% 
in females versus 66.2% in males (p  <  0.05). Lower survival 
and less frequent antenatal corticosteroid use in males directly 
reflected the higher rate of CLD found in this group (25.7% males 
versus 18.9% females, p < 0.05). This study captured outcomes 
in the immediate period following widespread support for use 
of antenatal corticosteroids. A subsequent study of over 2,700 
Canadian neonates born between 24 and 26 weeks from 2000 to 
2005 supported the previous findings by Jones showing mortality 
was higher in the male cohort (OR 0.78, CI 0.62–0.99) (22). The 
authors of this study concluded that males delivered between 24 
and 26 weeks in the post-surfactant era remain at higher risk of 
mortality than girls despite equal exposure to antenatal corticos-
teroids. To further investigate the effect of antenatal corticosteroid 
use on neonatal mortality, Fanaroff compared neonatal death in 
VLBW infants in the immediate postnatal–antenatal steroid era 
(1995–1996) to the outcomes of neonates over the next 6 years 
(1997–2002). There was no significant increase in survival with-
out neonatal and long-term morbidity between the two cohorts. 
Females in both groups had higher survival rates with observed 
functional maturity superior to gestational age and birthweight 
matched males (23).
LPT and Gender Differences in Mortality
Recently, there has been a focus on the LPT neonate and the 
disparity in mortality this cohort faces compared to infants born 
at term. In a study of 252 LPT infants, mortality was higher for 
this cohort compared to term infants (2.3 versus 0%, p = 0.04) 
with male gender highlighted as an independent risk factor in 
this cohort (24). Given the low rate of mortality in the LPT group 
compared to neonates born at less than 34 weeks, many studies 
have chosen to highlight the primary contributor to mortality 
in LPT infants, respiratory morbidity, as opposed to mortality. 
In 2016, the authors of a prospective randomized controlled 
trial demonstrated a 20% reduction in their composite primary 
outcome that included need for CPAP, supplemental oxygen, 
and mechanical ventilation for LPT infants given betamethasone 
(p = 0.02) (11). These LPT infants were also found to have lower 
rates of transient TTN (p  =  0.002), required less surfactant 
(p = 0.03), and had lower rates of BPD (p = 0.04). This study was 
not powered to show a difference in mortality and furthermore 
did not provide results stratified by gender. With the new rec-
ommendation of antenatal corticosteroids for this LPT group, 
further investigation is needed to determine whether the male 
sex contribution to mortality risk in LPT infants persists with 
steroid administration.
eXPLORiNG THe ORiGiNS OF GeNDeR 
DiFFeReNCeS iN NeONATAL 
ReSPiRATORY MORBiDiTY  
AND MORTALiTY
The apparent male disadvantage in morbidity and mortality has 
again been highlighted in this review. We present the clinical evi-
dence from the past three decades that continues to support a sex 
disparity despite the advent of antenatal corticosteroid adminis-
tration and postnatal surfactant use. From a basic macroscopic 
level, male fetuses tend to weigh more at any given gestational 
age and thus tend to have more alveoli and alveolar surface area 
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than gestational age-matched females (22, 25, 26). Surfactant 
production, however, has been shown to appear earlier in female 
lung development than in males (27). This earlier presence of 
surfactant seems to prevent the early closure of female alveoli 
and small airways, which may contribute to the higher airflow 
and decreased resistance found in the female respiratory system. 
Fleisher et al. showed that both the 2:1 lecithin/sphingomyelin 
(L/S) ratio and the appearance of phosphatidylglycerol, a com-
ponent of surfactant, occurred a week earlier in females than 
males (27).
As mentioned before, antenatal corticosteroid administra-
tion reduces respiratory morbidity and thus decreases neonatal 
mortality. Corticosteroids have been shown to upregulate airway 
Na+–K+ pump activity which facilitates shunting of fluid out of the 
fetal lung (28). Uncleared fluid within the fetal lung predisposes 
neonates to RDS. However, despite equal administration of ante-
natal corticosteroids, we continue to see RDS at a higher rate in 
males. This may be explained by the fact that male neonates have 
lower rates of alveolar sodium transport channels than females 
(29). A decrease in sodium transport channels may contribute to 
fluid accumulation in the lung which would hinder gas exchange 
and increase the risk of RDS.
Sex hormones have also been shown to have an effect on the 
development of the fetal lung. When analyzing the components 
of fetal lung tissue, androgen receptors are found in higher 
density on the surface of the epithelial cells that modulate 
bronchiole budding in the early fetal lung (30). These same cells 
express 5-alpha reductase in their cytoplasm in high amounts 
which may indicate dihydrotestosterone, and other androgens 
have an effect on the initial development of the bronchiole tree 
(30). Androgens have also been shown to inhibit surfactant 
production by altering epidermal growth factor and transform-
ing growth factor β1 (31). Higher levels of androgens decrease 
the activity of these two transcription factors in type II alveolar 
cells downregulating production of surfactant. One animal 
study showed that female rabbits given androgens in utero had 
delayed lung development while mothers with male offspring 
given antiandrogens showed no sex difference in surfactant 
production compared to normal females (25). The male disad-
vantage is not simply a consequence of surfactant insufficiency 
but is also driven by the negative effect exhibited by androgens 
on alveolar cells.
Alternatively, estrogen has been shown to also influence lung 
development (32). This mechanism has been postulated to occur 
through the platelet derived growth factor and granulocyte-
macrophage colony-stimulating factor signaling pathways which 
cause defects in alveolar structure, lung elasticity, and surfactant 
production (33). Deletion of estrogen receptor β in female mice 
causes an increase in alveolar size and a decrease in alveolar sur-
face area making these mice more like their male counterparts. 
This difference can strongly impact the risk of developing RDS 
in preterm neonates as the decreased surfactant and recoil of the 
lung contributes to a lower probability of gas exchange in alveoli. 
The constellation of gender differences described is illustrated in 
Figure 1.
Contributing Factors to Gender 
Differences in Preterm Neonatal 
Respiratory Morbidity and Mortality
Figure 1 describes the genetic, hormonal, and functional differ-
ences between genders that may explain the disparity in respira-
tory morbidity and mortality between males and females.
CONCLUSiON
For the past century, researchers have underscored the “male 
disadvantage” observed in respiratory morbidity and mortality 
FiGURe 1 | Contributing factors to gender differences in neonatal respiratory morbidity and mortality.
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continue to see stark differences between males and females in 
regards to acute and CLD as well as mortality. Sex differences in 
physiology, hormones, and growth factors are fundamentally at 
the root of this disparity. With this knowledge, new endeavors 
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